The Effects of Leucine and Isoleucine on Glucose Metabolism
Condition: Hyperglycemia
MeSH terms: Hyperglycemia
Study type: Interventional

Summary: 
      Diabetes is classified as an impairment of the body's ability to control blood glucose
      levels. Uncontrolled hyperglycemia can give rise to macrovascular (i.e., heart disease and
      stroke) and microvasculature damage such as retinopathy, nephropathy and neuropathy. These
      comorbidities may definitively reduce quality of life.

      Hypotheses to be tested:

        1. The ingestion of amino acids L-Isoleucine and L-Leucine at a therapeutic dose prior to a
           glucose load will concurrently and independently improve glucose tolerance.

        2. The ingestion of L-Isoleucine and L-Leucine separately or together will have a minimal
           effect on incretin responses of Glucagon-like peptide-1 and Glucose-dependent
           insulinotropic peptide (GLP-1, GIP).
    

Detailed description: 
      Specific Aims and Hypothesis Diabetes is classified as an impairment of the body's ability to
      control blood glucose levels. Uncontrolled hyperglycemia can give rise to macrovascular
      (i.e., heart disease and stroke) and microvasculature damage such as retinopathy, nephropathy
      and neuropathy. These comorbidities may definitively reduce quality of life.

      Hypotheses to be tested:

        1. The ingestion of amino acids L-Isoleucine and L-Leucine at a therapeutic dose prior to a
           glucose load will concurrently and independently improve glucose tolerance.

        2. The ingestion of L-Isoleucine and L-Leucine separately or together will have a minimal
           effect on incretin responses (GLP-1, GIP).

      Specific Aims:

        1. Specific Aim I will test the hypothesis that the ingestion of amino acids L-Isoleucine
           and L-Leucine at a therapeutic dose prior to a glucose load will concurrently and
           independently improve glucose tolerance.

        2. Specific Aim II will test the hypothesis that the ingestion of L-Isoleucine and
           L-Leucine will have a minimal effect on incretin responses in conjunction with prior
           research.
    

Intervention name(s): Leucine Supplement; Isoleucine Supplement; Leucine Supplement combined with Isoleucine Supplement
Intervention type(s): Dietary Supplement; Dietary Supplement; Dietary Supplement
Intervention description(s): For this visit participants will ingest a powdered form of Leucine in the amount of 0.3g/kg of lean body mass weight with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution; For this visit participants will ingest a powdered form of Isoleucine in the amount of 0.3g/kg of lean body mass weight with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution.; For this visit participants will ingest a powdered form of Leucine and Isoleucine in the amount of 0.3g/kg of lean body mass weight (equal in total dosage to other treatments) with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary purpose: Basic Science
Keywords: leucine; isoleucine